Pfizer releases data on oral COVID-19 antiviral treatment candidate, says pill reduces risk of hospitalization or death by 89%
Pfizer today unveiled the first phase 2/3 clinical trial data on its oral COVID-19 antiviral treatment, declaring its candidate to be highly effective in reducing the risk of hospitalization or death from severe COVID-19. Pfizer said the drug, Paxlovid, when administered within five days of the appearance of COVID-19 symptoms, yielded an 89% reduction in deaths or hospitalizations through 28 days. Pfizer said it will submit the data to the Food and Drug Administration in support of its rolling submission for an emergency use authorization.
Related News Articles
Headline
AHA today participated in a Centers for Disease Control and Prevention Fall Immunization Kick-off Event for partner organizations, which focused on vaccinating…
Headline
As authorized yesterday by the Food and Drug Administration and recommended by its vaccine advisory committee, the Centers for Disease Control and Prevention…
Headline
Under the Department of Health and Human Services’ recent agreement with Regeneron to develop a new monoclonal antibody to prevent COVID-19, the U.S. list…
Headline
In time for back-to-school health screenings, AHA Aug. 25 released an infographic on strategies that clinicians and the Centers for Disease Control and…
Headline
Receiving a COVID-19 mRNA vaccine or booster during pregnancy can benefit pregnant people and their newborn infants, according to findings from a federally…
Chairperson's File
It’s been about 65 years since an effective vaccine was first used worldwide against poliomyelitis, or polio. Until then, polio was responsible for about 500,…